Evidence map›Paper›PMID 41535831›Full record

ArticleCancer cell international2026

SPP1 promotes cancer stemness and reduces osimertinib sensitivity in non-small cell lung cancer through interactions with CD44.

Hong Bi, Lewei He, Liyan Wang, Lijuan Yang, Jing Shao, Hang Li, Xiang Guo, Hong Liu, Yaping Fu, Huiming Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hong Bi *Department of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Lewei He *Department of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Liyan Wang *Department of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Lijuan YangDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Jing ShaoDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Hang LiDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Xiang GuoDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Hong LiuDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Yaping FuDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Huiming WangDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Yue WangDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China.
Zhixian JinDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China. jinzhixian@kmmu.edu.cn.
Min ChenDepartment of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunming City and Affiliated Calmette Hospital of Kunming Medical University, Kunming, 650224, Yunnan Province, China. chenminn@kmmu.edu.cn.

Funding

National Nature Science Foundation of China 82160593Yunnan Applied Basic Research Projects 202101AY070001-213Yunnan Applied Basic Research Projects 202201AY070001-197Yunnan Applied Basic Research Projects 202501AS070008Yunnan Li Qiang Expert Workstation 202305AF150137
6 · The paper itself

Abstract

Non-small cell lung cancer (NSCLC) constitutes a significant proportion of lung cancers and poses a serious threat to human health. Osimertinib is the first-line drug for treating NSCLC, but long-term use can lead to drug resistance. Exploring the mechanism of drug resistance and effectively selecting treatment plans based on the mechanism of resistance are urgent issues to be addressed. In this study, dryness characteristics were evaluated by measuring cell activity, cell spheroid formation and cloning conditions, and the levels of stem cell marker molecules. The sensitivity of SPP1 to osimertinib was also assessed in mice. The results showed that SPP1 regulates cancer stem cells (CSCs) by interacting with CD44, thereby generating osimertinib resistance. These findings provide a basis for clinical research.

Indexed as

Cancer stem cellEGFR mutationNon-small cell lung cancerOsimertinib resistanceSPP1

Identifiers

PMID41535831
PMCPMC12888251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.